The Advisory Committee on Immunization Practices (ACIP) voted 5-2 to endorse Merck’s RSV monoclonal antibody, Enflonsia, for infants during their first respiratory syncytial virus (RSV) season if not protected by maternal vaccination. This recommendation marks a significant step in protecting vulnerable infants from RSV, corroborated by the subsequent inclusion of monoclonals into the Vaccines for Children program, ensuring broader vaccine access for pediatric populations.